Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5)

被引:26
|
作者
Palte, Rachel L. [1 ]
Schneider, Sebastian E. [1 ]
Altman, Michael D. [1 ]
Hayes, Robert P. [2 ]
Kawamura, Shuhei [1 ]
Lacey, Brian M. [1 ]
Mansueto, My Sam [1 ]
Reutershan, Michael [1 ]
Siliphaivanh, Phieng [1 ]
Sondey, Christopher [1 ]
Xu, Haiyan [1 ]
Xu, Zangwei [1 ]
Ye, Yingchun [1 ]
Machacek, Michelle R. [1 ]
机构
[1] Merck & Co Inc, Computat & Struct Chem, Boston, MA 02115 USA
[2] Computat & Struct Chem, West Point, PA 19486 USA
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2020年 / 11卷 / 09期
关键词
PRMT5; allosteric inhibition; methyltransferase; peptide competitive; SAM competitive; crystal structure; SELECTIVE INHIBITOR; METHYLATION; POTENT; DISCOVERY; DELETION; HISTONE;
D O I
10.1021/acsmedchemlett.9b00525
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Protein arginine methyltransferase 5 (PRMT5) belongs to a family of enzymes that regulate the posttranslational modification of histones and other proteins via methylation of arginine. Methylation of histones is linked to an increase in transcription and regulates a manifold of functions such as signal transduction and transcriptional regulation. PRMT5 has been shown to be upregulated in the tumor environment of several cancer types, and the inhibition of PRMT5 activity was identified as a potential way to reduce tumor growth. Previously, four different modes of PRMT5 inhibition were known-competing (covalently or non-covalently) with the essential cofactor Sadenosyl methionine (SAM), blocking the substrate binding pocket, or blocking both simultaneously. Herein we describe an unprecedented conformation of PRMT5 in which the formation of an allosteric binding pocket abrogates the enzyme's canonical binding site and present the discovery of potent small molecule allosteric PRMT5 inhibitors.
引用
收藏
页码:1688 / 1693
页数:6
相关论文
共 50 条
  • [1] Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors
    Lin, Hong
    Luengo, Juan, I
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (11) : 1264 - 1269
  • [2] Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders
    Shen, Yudao
    Gao, Guozhen
    Yu, Xufen
    Kim, Huensuk
    Wang, Li
    Xie, Ling
    Schwarz, Megan
    Chen, Xian
    Guccione, Ernesto
    Liu, Jing
    Bedford, Mark T.
    Jin, Jian
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (17) : 9977 - 9989
  • [3] Protein Arginine Methyltransferase 5 (PRMT5) Mutations in Cancer Cells
    Rasheed, Shayaan
    Bouley, Renee A.
    Yoder, Ryan J.
    Petreaca, Ruben C.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)
  • [4] Research Progress on Small-molecule Inhibitors of Protein Arginine Methyltransferase 5 (PRMT5) for Treating Cancer
    Guo, Chaohua
    Wu, Lintao
    Zheng, Xumei
    Zhao, Lin
    Hou, Xiaojia
    Wang, Zhijun
    Han, Chun
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2023, 23 (21) : 2048 - 2074
  • [5] Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies
    Zheng, Jiahong
    Li, Bang
    Wu, Yingqi
    Wu, Xiaoshuang
    Wang, Yuanxiang
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (13) : 8407 - 8427
  • [6] Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery
    Wang, Yuanxiang
    Hu, Wenhao
    Yuan, Yanqiu
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (21) : 9429 - 9441
  • [7] Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells
    Mongiardi, Maria Patrizia
    Savino, Mauro
    Bartoli, Laura
    Beji, Sara
    Nanni, Simona
    Scagnoli, Fiorella
    Falchetti, Maria Laura
    Favia, Annarita
    Farsetti, Antonella
    Levi, Andrea
    Nasi, Sergio
    Illi, Barbara
    SCIENTIFIC REPORTS, 2015, 5
  • [8] Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors
    Lin, Hong
    Wang, Min
    Zhang, Yang W.
    Tong, Shuilong
    Leal, Raul A.
    Shetty, Rupa
    Vaddi, Kris
    Luengo, Juan I.
    ACS MEDICINAL CHEMISTRY LETTERS, 2019, 10 (07): : 1033 - 1038
  • [9] Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review
    Feustel, Kavanya
    Falchook, Gerald S.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2022, 5 (03) : 58 - 67
  • [10] Genetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma
    Yan, Fengting
    Alinari, Lapo
    Lustberg, Mark E.
    Martin, Ludmila Katherine
    Cordero-Nieves, Hector M.
    Banasavadi-Siddegowda, Yeshavanth
    Virk, Selene
    Barnholtz-Sloan, Jill
    Bell, Erica Hlavin
    Wojton, Jeffrey
    Jacob, Naduparambil K.
    Chakravarti, Arnab
    Nowicki, Michal O.
    Wu, Xin
    Lapalombella, Rosa
    Datta, Jharna
    Yu, Bo
    Gordon, Kate
    Haseley, Amy
    Patton, John T.
    Smith, Porsha L.
    Ryu, John
    Zhang, Xiaoli
    Mo, Xiaokui
    Marcucci, Guido
    Nuovo, Gerard
    Kwon, Chang-Hyuk
    Byrd, John C.
    Chiocca, E. Antonio
    Li, Chenglong
    Sif, Said
    Jacob, Samson
    Lawler, Sean
    Kaur, Balveen
    Baiocchi, Robert A.
    CANCER RESEARCH, 2014, 74 (06) : 1752 - 1765